Micromet

Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203

BETHESDA, Md., June 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the initiation of the first clinical trial for the anti-granulo...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...ne 30, 2009. In the second quarter of 2009, micromet achieved a number of significant milestones illust...urther summarized below: On April 22, micromet presented preclinical data showing activity in viv...utated tumor cells to those monoclonal antibodies. micromet also presented data at the AACR meeting indicating...

DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller

...ce primarily in publicly held life science companies. Prior to joining DOR, he served in the senior financial roles for VioQuest Pharmaceuticals Inc., micromet Inc., Cytogen Corporation and Genaera Corporation, all publicly traded, R&D-focused companies in the biotechnology and specialty pharmaceuticals a...

Micromet, Inc. Reports First Quarter 2009 Financial Results

...March 31, 2009. In the first quarter of 2009, micromet achieved a number of significant milestones illust...ummarized below: On January 12, micromet announced the execution of an option, collaboratio...ing Pharma AG. Under the terms of this agreement, micromet granted Bayer Schering Pharma an exclusive option ...

Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference

...treatment of patients with non-Hodgkin's lymphoma. micromet is developing blinatumomab in collaboration with M...tibody that targets EpCAM-expressing solid tumors. micromet is developing adecatumumab in collaboration with M...eatment of patients with metastatic breast cancer. micromet licensed a fourth clinical stage antibody, MT293, ...

New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110

...treatment of patients with non-Hodgkin's lymphoma. micromet is developing blinatumomab in collaboration with M...tibody that targets EpCAM-expressing solid tumors. micromet is developing adecatumumab in collaboration with M...eatment of patients with metastatic breast cancer. micromet has licensed a fourth clinical stage antibody, MT2...

Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting

...treatment of patients with non-Hodgkin's lymphoma. micromet is developing blinatumomab in collaboration with M...tibody that targets EpCAM-expressing solid tumors. micromet is developing adecatumumab in collaboration with M...eatment of patients with metastatic breast cancer. micromet has licensed a fourth clinical stage antibody, MT2...

Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference

...treatment of patients with non-Hodgkin's lymphoma. micromet is developing blinatumomab in collaboration with M...tibody that targets EpCAM-expressing solid tumors. micromet is developing adecatumumab in collaboration with M...eatment of patients with metastatic breast cancer. micromet licensed a fourth clinical stage antibody, MT293, ...

Micromet, Inc. Reports Second Quarter 2008 Financial Results

...e 30, 2008. Summary of Recent Events: In June, micromet and MedImmune presented a clinical update for the ... 2 clinical trial of blinatumomab. Also in June, micromet received a milestone payment of $775,000 from Nyco... inflammatory and autoimmune diseases. In April, micromet announced the initiation of the first phase 1 clin...

Micromet, Inc. Reports First Quarter 2008 Financial Results

...2008. Summary of Recent Events: -- In April, micromet announced the initiation of the first phase 1 ...ecurrence of these cancers. -- Also in April, micromet presented five posters at the American Associa... EpCAM in a relevant animal species. -- In March, micromet established a scientific advisory board and named ...

Micromet in Medical Technology

MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule

- New Compound Targeting Receptor Tyrosine Kinase EphA2 Shows Tumor Destruction at Low Dose Levels in Preclinical Models - GAITHERSBURG, Md. and CARLSBAD, Calif., April 19, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. and Micromet, Inc. today announced that published proof-of-concept data with a...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...t no. 482 Webcast/Conference Call micromet will host a webcast/conference call this morning f...eatment of patients with cancer. In addition, micromet has established a collaboration with Nycomed for t...uman antibody MT228 for the treatment of melanoma. micromet also has entered into an option, collaboration and...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...act number 267 Webcast/Conference Call micromet will host a webcast/conference call this morning f...eatment of patients with cancer. In addition, micromet has established a collaboration with Nycomed for t...uman antibody MT228 for the treatment of melanoma. micromet also has entered into an option, collaboration and...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...iation of a pivotal trial for ALL next year," said micromet President and CEO Christian Itin. "Micromet contin...s available at www.micromet-inc.com . About micromet Micromet, Inc. ( www.micromet-inc.com ) is a...tibody that targets EpCAM-expressing solid tumors. micromet is developing adecatumumab in collaboration with M...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

...ACR). These non-clinical data indicate that after micromet developed BiTE antibodies from the EGFR-specific m...R. et al., Science 321: 974-977 (2008) About micromet Micromet, Inc. ( www.micromet-inc.com ) is...tibody that targets EpCAM-expressing solid tumors. micromet is developing adecatumumab in collaboration with M...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

...artner Nycomed for the anti-GM-CSF antibody MT203. micromet received a payment of 1.5 million Euro (US$ 2.0 mi... Under a 2007 agreement between the two companies, micromet and Nycomed are developing MT203, a human anti-GM-... start of clinical trials with MT203." About micromet Micromet, Inc. ( www.micromet-inc.com ) is a...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

...dlinger et al., Lancet 2008; 371: 1007 About micromet Micromet, Inc. ( www.micromet-inc.com ) is a...tibody that targets EpCAM-expressing solid tumors. micromet is developing adecatumumab in collaboration with M...eatment of patients with metastatic breast cancer. micromet licensed a fourth clinical stage antibody, MT293, ...

Micromet Key Events for 2009

... key events anticipated for the year 2009. micromet intends to provide an update on its research and d...ted to complete a clinical phase 1 trial. micromet intends to publish results from the research and d...entific and clinical journals throughout the year. micromet also intends to enter into one to two new collabor...

Micromet Expands Committed Equity Financing Facility to $75 Million

...f newly-issued shares of Micromet's common stock. micromet has no obligation to access the facility and will ...ng financial position. The expanded CEFF provides micromet with additional financial strength and flexibility...ffective the registration statement to be filed by micromet covering the resale of the shares of common stock ...

Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells

...entific officer for Micromet. "In the near future, micromet will initiate a phase 2 study investigating the ac...he human immune system, to eliminate cancer cells. micromet is developing blinatumomab in collaboration with M...body in clinical trials, and is being developed by micromet in a phase 1 clinical trial for the treatment of p...

Micromet in Biological Technology

Micromet Closes $80.5 Million Public Offering of Common Stock

...previously announced public offering of 14,000,000 shares of common stock. micromet also announced that the underwriters for the offering have exercised in ful...lid tumors is being developed in collaboration with MedImmune. In addition, micromet has entered into an option, collaboration and license agreement with Bayer ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...s a patient's T cells to seek out and destroy cancer cells. In June, micromet announced that the company had achieved its primary endpoint in an ongoing ...lid tumors is being developed in collaboration with MedImmune. In addition, micromet has entered into an option, collaboration and license agreement with Bayer ...

Micromet Announces Pricing of Public Offering of Common Stock

... platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusi...

Micromet Announces Public Offering of Common Stock

... platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusi...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

...pean Time) to discuss its financial results for the second quarter of 2009. micromet anticipates releasing its financial results at 7:00 am Eastern Time (1:00 p...lid tumors is being developed in collaboration with MedImmune. In addition, micromet has entered into an option, collaboration and license agreement with Bayer ...

Micromet Added to Russell 3000 Index

...tment performance, market movements and market trends. We are pleased that micromet has been added to the Russell 3000 Index and expect that it will increase o...lid tumors is being developed in collaboration with MedImmune. In addition, micromet has entered into an option, collaboration and license agreement with Bayer ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

...clinical trial for the treatment of patients with cancer. In addition, micromet has established a collaboration with Nycomed for the development and commer...et's glycolipid-binding human antibody MT228 for the treatment of melanoma. micromet also has entered into an option, collaboration and license agreement with B...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

...compared to patients with low EpCAM expression(2). micromet is currently also conducting a randomized phase 2 ...eatment of patients with cancer. In addition, micromet has established a collaboration with Nycomed for t...uman antibody MT228 for the treatment of melanoma. micromet also has entered into an option, collaboration and...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

...8 and efficacy data from additional patients. micromet also announced a poster presentation(3) for adecat...accessed at http://www.asco.org . About micromet Micromet, Inc. ( www.micromet-inc.com ) is...tibody that targets EpCAM-expressing solid tumors. micromet is developing adecatumumab in collaboration with M...

Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009

...s financial results for the first quarter of 2009. micromet anticipates releasing its financial results at 7:0...8 (international), passcode: 58046416. About micromet Micromet, Inc. ( www.micromet-inc.com ) is a...tibody that targets EpCAM-expressing solid tumors. micromet is developing adecatumumab in collaboration with M...